We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Tests to Assess Risk of Hereditary Colon Cancer

By HospiMedica staff writers
Posted on 29 May 2002
Tests have been developed that detect genetic mutations predictive of hereditary colon cancer. More...
One test detects mutations in the APC gene, which causes familial adenomatous polyposis (FAP), a hereditary form of colon cancer that may cause up to 20% of hereditary disease. A second test identifies mutations unassociated with polyp formation.

The test that detects APC mutations is called Colaris AP, and this test also detects a more common variation of FAP known as attenuated FAP (aFAP), which may account for 20% of all colon cancer cases. The second test, for hereditary cancer unassociated with polyp formation, is called Colaris. Together, the two tests may detect about 90% of all hereditary colon cancer, states the developer, Myriad Genetics, Inc. (Salt Lake City, UT, USA). Each test provides a full-sequence DNA analysis to detect genetic mutations. Early detection may prevent the spread of colon cancer.

The average age at diagnosis of colon cancer among FAP patients is 35. Myriad advises that in addition to direct testing for Colaris AP, people with a family history of colon cancer who are negative on this test should consider adding the Colaris test to rule out the other major hereditary colon cancer syndrome. The company has introduced an accelerated turnaround version of Colaris, called Rapid Colaris. This version is designed to help doctors determine the best procedure for patients awaiting surgery following a diagnosis of colon cancer.

"Colaris AP extends our existing franchise with oncologists and cancer centers, providing a one-stop shop for hereditary colon cancer prediction and diagnosis,” said Gregory Critchfield, M.D., president of Myriad Genetic Laboratories, Inc.




Related Links:
Myriad

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Electrode Solution and Skin Prep
Signaspray
Radiology System
Riviera SPV AT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.